Imatinib Base

Imatinib Base About

Imatinib Base (CAS No. 152459-95-5), also known as Imatinib, CGP57148B, or by its marketed form as the active ingredient in Gleevec (also sold as Glivec), is a selective tyrosine kinase inhibitor widely used in oncology. It specifically targets the BCR-ABL fusion protein produced by the Philadelphia chromosome abnormality, as well as other tyrosine kinases such as c-KIT and PDGFR. Imatinib Base is the free base form of imatinib, typically used in pharmaceutical manufacturing before conversion into its mesylate salt form. It is primarily indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), and is also used in gastrointestinal stromal tumors (GISTs) and certain other rare malignancies driven by kinase mutations. Its development marked a breakthrough in targeted cancer therapy by offering a mechanism-based treatment with improved specificity compared to traditional chemotherapy.